万赛维上市了吗？

(valgansiklovir) is an oral anti-cytomegalovirus infection drug that combines the advantages of oral administration and intravenous injection. Just taking 2 tablets of valgansiklovir per day can effectively prevent and treat cytomegalovirus infection, avoid the direct and indirect harm caused by cytomegalovirus infection, and significantly improve the patient's quality of life and long-term survival rate.

Is valgansiklovir on the market?

Valgansiklovir was approved by the US FDA in May 2001. It is clinically used to treat acute retinitis caused by CMV infection in patients with acquired immunodeficiency syndrome. In May 2003, its indications were expanded to prevent and treat secondary CMV infection in organ transplant recipients.

Valgansiklovir is administered orally and should be taken with food. Valgansiklovir is rapidly and massively converted into ganciclovir. The bioavailability of valgansiklovir as measured by ganciclovir is 10 times higher than that of ganciclovir capsules, so the dosage and usage instructions for valgansiklovir described below should be strictly followed.

Induction therapy of CMV retinitis: For patients with active CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) twice daily for 21 days. Prolonged induction therapy may increase the risk of bone marrow toxicity.

Maintenance treatment of CMV retinitis: After induction therapy, or in patients with inactive CMV retinitis, the recommended dose is 900 mg (two 450 mg tablets) once daily. Induction therapy may be repeated in patients with worsening retinitis.

Prevention of CMV infection in transplant patients: For patients who have received solid organ transplants, the recommended dose is 900 mg (two 450 mg tablets) once daily, starting within 10 days after transplantation and continuing until 100 days after transplantation.

(valgansiklovir) adverse events (% of patients) were diarrhea (30%), tremor (28%), graft rejection (24%), nausea (23%), headache (22%), leg edema (21%), constipation (20%), back pain (20%), insomnia (20%), hypertension (18%), and vomiting (16%).